Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.

CONCLUSION: Double CD25+/CD123+ co-expression in AML patients is a dismal prognostic marker and could be used as novel biomarker for risk stratification for AML patients. PMID: 32417762 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32417762?dopt=Abstract

Source: Cancer Biomarkers : Section A of Disease Markers - May 8, 2020 Category: Cancer & Oncology Authors: Aref S, Azmy E, El Ghannam D, Haroun M, Ibrahim L, Sabry M Tags: Cancer Biomark Source Type: research